# Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve

> **NCT02679261** · PHASE3 · COMPLETED · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 220 (actual)

## Conditions studied

- Bicuspid Aortic Valve

## Interventions

- **DRUG:** Atorvastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02679261
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2021-02
- **Final completion:** 2021-02
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02679261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02679261, "Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02679261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*